通过多价值调节血脑屏障运输的快速粉样蛋白β清除和认知恢复
Junyang Chen1,2,3,4,5, Pan Xiang1,2, Aroa Duro-Castano4,6
1Department of Radiology, Huaxi MR Research Center (HMRRC), Institute of Radiology and Medical Imaging, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Signal transduction and targeted therapy
|October 6, 2025
概括
这项研究引入了一种针对血脑屏障 (BBB) 的新型纳米药物,以清除阿尔茨海默病 (AD) 模型中的粉样蛋白β斑块. 在小鼠中,治疗显著改善了认知功能,并降低了大脑粉样蛋白水平.
科学领域:
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
- 药理学 药理学是指药理学的学科.
背景情况:
- 血脑屏障 (BBB) 对于中枢神经系统的保护至关重要,但其功能障碍有助于阿尔茨海默氏病 (AD) 的发病.
- 粉样β (Aβ) 斑块在大脑中的积累是AD的标志.
- 准BBB传输机制为AD提供了一个潜在的治疗策略.
研究的目的:
- 开发和评估一种针对BBB上的低密度脂蛋白受体相关蛋白1 (LRP1) 的新型纳米医学策略.
- 通过调节LRP1介导的运输来增强Aβ从大脑中的清除.
- 在AD小鼠模型中评估这种方法的治疗疗效.
主要方法:
- 设计LRP1向的聚合体体,以调节受体介导运输.
- 向AD模型小鼠注射聚合体.
- 使用ELISA量化大脑和血Aβ水平.
- 使用成像技术评估Aβ斑块负担.
- 通过空间学习和记忆测试来评估认知功能.
主要成果:
- 在AD模型小鼠中,LRP1向的聚合体显著降低了近45%的脑Aβ水平.
- 血Aβ水平在治疗后2小时内增加了8倍,表明清除得到了改善.
- 图像检测证实大脑Aβ信号的减少.
- 被治疗的AD小鼠在空间学习和记忆方面显著改善,与野生类型小鼠相比.
- 认知效益持续长达6个月.
结论:
- 通过使用新型纳米药物通过LRP1调制准BBB是阿尔茨海默病的有希望的治疗策略.
- 这种方法有效地促进了Aβ清除,并在AD小鼠模型中恢复认知功能.
- 纳米药物的超分子设计可以在膜贩运水平上引起生物作用,为药物开发开辟新的途径.
更多相关视频
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
44.2K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.4K
相关概念视频
Alzheimer's Disease: Treatment
822
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822
The Blood-brain Barrier
52.3K
Overview
52.3K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
